Curaleaf International Is Beating Illicit Cannabis Prices In UK And Germany - What's Next For EU Expansion?

Curaleaf International CURLF, a leading cannabis company, is expanding its footprint across the UK, Germany and Poland. This strategic expansion is not only about entering new markets but also about outpricing the illegal cannabis trade. What drives their decision to enter specific markets? How do they navigate the complex regulatory landscape?

Curaleaf recently announced a first-quarter revenue of $339 million, reflecting a 2% increase year-over-year with an adjusted gross margin of 48%. Despite a net loss of $48.3 million due to ongoing investments, the company's market cap stands at $4.12 billion.

In an exclusive interview with Benzinga Cannabis, Juan Martinez, head of Curaleaf International discussed strategic moves, market potential, and future growth plans, offering valuable insights for investors.

Market Potential In UK And Germany

The UK market presents significant growth opportunities for Curaleaf International. According to Martinez, reports indicate that over 2 million adults in the UK self-medicate with cannabis, yet only 45,000 are official patients. This significant discrepancy highlights a potential 40-fold growth if awareness and regulatory frameworks improve.

"In the UK, there's a massive growth potential," Martinez said. "The latest reports from the government say over 2 million adults are self-medicating with cannabis, while the current patient numbers are just 45,000. This gap shows a substantial opportunity for growth as we work to increase awareness and push for better regulations."

Similarly, Germany offers a promising market. Following regulatory changes on April 1st, the patient base in Germany doubled. Martinez pointed out that Germany's current 200,000 patients represent only a small fraction of the potential market.

"To put it in perspective, Germany has a population of 84 million, and we estimate that the market potential is around 3.5 million patients," he said. "This is significantly higher than the current patient base and shows over 20 times growth from where we are now."

Changing Regulations And Increasing Acceptance Of Medical Cannabis

The rationale behind Curaleaf's expansion into these markets is multi-faceted. Martinez emphasizes that changing regulations and increasing acceptance of medical cannabis are critical factors.

"In both the UK and Germany, cannabis regulation is becoming increasingly normalized," he noted. "It's no longer a taboo or radical position. Instead, it has become very pragmatic, driven by real-world examples and the need for better healthcare alternatives."

Martinez also highlights the importance of regulatory support in driving market expansion. "In the UK, the creation of private clinics has been a step forward, but we believe involving the NHS would greatly enhance access and awareness," he told Benzinga. "Similarly, in Germany, the changes in regulation, such as the recent introduction of Pillar One, have already doubled the patient base, indicating a strong potential for further growth as more regulatory improvements are implemented."

Product Development And Market Adaptation

Curaleaf adapts its product offerings based on scientific data and market demands.

Martinez noted that Curaleaf is collecting real-world evidence on how their products affect patients with various conditions. "Right now, we're treating around 16 different conditions in our clinics in the UK, the highest being chronic pain," he said. "By the time we complete a product, we don't just approach German regulators saying we want to launch vapes. We present a dossier of 50 pages with clear guidelines on formulation, opinions from doctors in the UK, and firsthand real-world evidence from patients in the UK showing how it helps their symptoms."

In the UK, Curaleaf introduced vapes and gummies collecting real-world evidence from over 30,000 patients. This approach allows them to tailor products to medical needs rather than consumer trends.

In Germany, strict regulations limit the types of cannabis products. Despite these constraints, Curaleaf is negotiating to introduce products like gummies, leveraging their UK experience to provide compelling evidence to German regulators.

Competitive Edge And Supply Chain

Curaleaf maintains its competitive edge through a robust supply chain and strategic acquisitions. The company's cultivation facilities in Portugal and Canada are ready to triple their output with minimal investment, ensuring consistent supply to meet growing demand.

Martinez explained that operations vary by country, using the UK as an example. "One major benefit of international markets is the absence of interstate commerce prohibition. We use Portugal and Northern Green in Canada as our cultivation hubs. For the UK market, products are shipped to Curaleaf Laboratories in northern England, which has a pharmacy license to dispense products via mail. Patients can receive prescriptions from our online clinics and have products delivered to their homes. This system is necessary because most UK pharmacies do not stock cannabis products," he said.

"In Germany, regulations require pharmacies to be owned by pharmacists, limiting them to three pharmacies each. This means no pharmacy chains like Walgreens exist. We have a wholesale license to bring in products from Portugal and Canada," Martinez added.

Curaleaf's acquisition of the 420 brand, which holds over a 20% market share, exemplifies their dominance in Germany. "The key in Germany is about continuity of supply," says Martinez, ensuring pharmacies remain well-stocked with consistent, high-quality products.

Addressing Awareness And Pricing

One of the biggest challenges Curaleaf faces is patient awareness. In both the UK and Germany, many potential patients are unaware of the legal medical cannabis programs.

Martinez pointed out that in the UK, the average price of pharmaceutical-grade cannabis is £5.50 per gram, compared to £10-15 on the illicit market, making it an attractive option for informed patients. Similarly, in Germany, legal cannabis costs €7 per gram, cheaper than the €10 illicit alternative.

Learn more about leading cannabis companies and stocks, at the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money, and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!

Photo: AI-Generated Image.